Recipient selection and management before cardiac transplantation

American Journal of the Medical Sciences

Volumn 314, Issue 3, 1997, Pages 139-152

  Frantz, Robert P ^a   Olson, Lyle J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cardiac transplantation; Management of severe congestive heart failure; Prognosis in congestive heart failure; Recipient selection

Indexed keywords

ARTICLE; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; FEMALE; FUNCTIONAL ASSESSMENT; HEART ARRHYTHMIA; HEART CATHETERIZATION; HEART TRANSPLANTATION; HUMAN; MALE; MORTALITY; PATIENT SELECTION; PROGNOSIS; SUDDEN DEATH;

EID: 0030881180     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199709000-00003     Document Type: Article

References (111)

1. Costanzo M, Augustin S, Bourge R, Bristow M, O'Connell JB, Driscoll D, et al. Selection and treatment of candidates for heart transplantation: A statement for health professionals. Circulation. 1995;92:3593-612.
2. Mudge GH, Goldstein S, Addonizio LJ, Caplan A, Mancini D, Levine TB, et al. Twenty-fourth Bethesda conference: Cardiac transplantation: Task Force 3: Recipient guidelines/priorization. J Am Coll Cardiol. 1993;22:21-31.
3. O'Connell JB, Bourge RC, Costanzo-Nordin M, Driscoll DJ, Morgan JP, Rose EA, et al. Cardiac transplantation: Recipient selection, donor procurement, and medical follow-up: A statement for health professionals from the Committee on Cardiac Transplantation of the Council on Clinical Cardiology. American Heart Association. Circulation. 1993;86:1051-78.
4. Stevenson LW, Hamilton MA, Tillisch JH, Moriguchi JD, Kobashigawa JA, Creaser JA, et al. Decreasing survival benefit from cardiac transplantation for outpatients as the waiting list lengthens. J Am Coll Cardiol. 1991;18:919-25.
5. Stevenson LW, Fowler MB, Schroeder JS, Stevenson WG, Dracup KA, Fond V. Poor survival of patients with idiopathic cardiomyopathy considered too well for transplantation. Am J Med. 1987;83:871-8.
6. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: The Framingham study. N Engl J Med. 1971;285:1441-6.
7. Massie BM, Conway M. Survival of patients with congestive heart failure: past, present, and future prospects. Circulation. 1987;75(suppl 4):IV11-9.
8. Cohn JN, Rector TS. Prognosis of congestive heart failure and predictors of mortality. Am J Cardiol. 1988;72:25A-30A.
9. Gradman A, Deedwania P, Cody R, Massie B, Packer M, Pitt B, Goldstein S. Predictors of total mortality and sudden death in mild to moderate heart failure: Captopril Digoxin Study Group. J Am Coll Cardiol. 1989;14:564-70.
10. Unverferth DV, Magorien RD, Moeschberger ML, Baker PB, Fetters JK, Leier CV. Factors influencing the one-year mortality of dilated cardiomyopathy. Am J Cardiol. 1984;54:147-52.
11. Schwartz F, Mall G, Zebe H, Schmitzer E, Manthey J, Scheurien H, et al. Determinants of survival in patients with congestive cardiomyopathy: Quantitative morphologic findings and left ventricular hemodynamics. Circulation. 1984;70:923-8.
12. Harston WE, Tristani FE, Dunkman WB, Jacobs W, Flohr KH, Goldman S, et al. Veterans Administration cooperative study on vasodilator therapy of heart failure: Influence of pre-randomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate. Circulation. 1987;75(suppl 4, pt 2):IV-49-54.
13. Stevenson LW, Allison JH, Hamilton M, Luu M, Chelimsky-Fallick C, Morguchi J, et al. Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than 20% secondary to ischemic or nonischemic dilated cardiomyopathy. Am J Cardiol. 1990; 66:1348-54.
14. Gradman AH, Deedwania PC. Predictors of mortality in patients with heart failure. Cardiol Clin. 1994;12:25-35.
15. Dee GW, Filer MA, Herrmann HC, Cocca-Spolford D, Semigrant MJ. Long-term outcome of enoximone therapy in patients with refractory heart failure. Am Heart J. 1993;125(pt 1):423-9.
16. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-35.
17. Bigger JT. Why patients with congestive heart failure die: Arrhythmias and sudden cardiac death. Circulation. 1987;75(suppl 4, pt 2):IV-28-35.
18. Franciosa JA. Why patients with heart failure die: Hemodynamic and functional determinants of survival. Circulation. 1987;75(suppl 4, pt 2):IV-20-7.
19. Franciosa JA, Wilen M, Ziesche S, Cohn JA. Survival in men with severe chronic left ventricular failure due to either coronary artery disease or idiopathic dilated cardiomyopathy. Am J Cardiol. 1983;51:831-6.
20. Califf RM, Bounous P, Harrell FE, McCants B, Lee KL, McKinnis RA, Rosati RA. The prognosis in the presence of coronary artery disease. In: Braunwald E, Mock MB, Watson JT, eds. Congestive Heart Failure: Current Research and Clinical Applications. New York: Grune & Stratton; 1982:31-40.
21. Franciosa JA. Why patients with heart failure die: Hemodynamic and functional determinants of survival. Circulation. 1987;75(suppl 4):IV20-IV27.
22. Keogh AM, Baron DW, Hickie JB. Prognostic guides in patients with idiopathic or ischemic dilated cardiomyopathy assessed for cardiac transplantation. Am J Cardiol. 1990;65:803-908.
23. Stevenson LW, Allison JH, Hamilton M, Luu M, Chelimsky-Fallick C, Morguchi J, et al. Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than 20% secondary to ischemic or nonischemic dilated cardiomoypathy. Am J Cardiol. 1990; 66:1348-54.
24. Likoff MJ, Chandler SL, Kay HR. Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol. 1987;59:634-8.
25. Franciosa JA, Wilen M, Ziesche S, Cohn JN. Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol. 1983;51:831-6.
26. Louie HW, Lake H, Milgaiter E, Drinkwater DC, Hamilton MA, Brunken RC, et al. Ischemic cardiomyopathy: criteria for coronary revascularization and cardiac transplantation. Circulation. 1991;84(suppl 3):III-290-5.
27. Alderman EL, Fisher LD, Lipwin P, Keiser GC, Myerx WO, Maynard C, et al. Results of coronary artery surgery in patients with poor left ventricular function (CASS). Circulation. 1983;68:789-99.
28. Bounous EP, Mark DB, Pollock BG, Hiatey MA, Harrell FE, Loc KL, et al. Surgical survival benefit for coronary disease patients with left ventricular dysfunction. Circulation. 1988;79(suppl 1, pt 2):I-191-7.
29. Hockbarg MS, Parnonnet V, Gielchinsky I, Husanin SM. Coronary artery bypass grafting in patients with ejection fraction below any percent: Early and late results in 466 patients. J Thorac Cardiovasc Surg. 1983;86:519-27.
30. Cosgrove DM, Loop FD, Lyela BW, Billiot R, Gill CC, Golding LA, et al. Primary myocardial revascularization: trends in surgical mortality. J Thorac Cardiovasc Surg. 1984;88(pt 1):673-84.
31. Dreyfus GD, Duhoe D, Biasco A, Vigoni F, Dubia C, Broadaty D, et al. Myocardial viability assessment in ischemic cardiomyopathy: Benefit of coronary revascularization. Ann Thorac Surg. 1994;57:1402-8.
32. Perrone-Filardi P, Pace L, Prastaro M, Squame F, Betocchi S, Soricelli A, et al. Assessment of myocardial viability in patients with chronic coronary artery disease. Circulation. 1996;94:2712-9.
33. Bonow RO, Borer JS, Rosing DR, Henry WL, Pearlman AS, McIntosh CL, et al. Preoperative exercise capacity in symptomatic patients with aortic regurgitation as a predictor of post-operative left ventricular function and long-term prognosis. Circulation. 1980;62:1280-90.
34. Bonow RO, Picone AL, McIntosh CL, Jones M, Rosing DR, Maron BJ, et al. Survival and functional results after valve replacement for aortic regurgitation from 1976 to 1983: Impact of preoperative LV function. Circulation. 1985;72:1244-56.
35. Lytle BW. Impact of coronary artery disease on valvular heart surgery. Cardiol Clin. 1991;9:301-14.
36. Zile MR. Chronic aortic and mitral regurgitation: Choosing the optimal time for surgical correction. Cardiol Clin. 1991;9:238-53.
37. Figulla HR, Rahlf G, Nieger M, Luig H, Kreuzer H. Spontaneous hemodynamic improvement or stabilization and associated biopsy findings in patients with congestive cardiomyopathy. Circulation. 1985;71:1095-1104.
38. O'Connell JB, Costanzo-Nordin MR, Subramanian R, Robinson JA, Wallis DE, Scanlon RJ, et al. Peripartum cardiomyopathy: Clinical, hemodynamic, histologic and prognostic characteristics. J Am Coll Cardiol. 1986;8:52-6.
39. Francis GS, Johnson TH, Ziesche S, Berg M, Boosalis P, Cohn JN. Marked spontaneous improvement in ejection fraction in patients with congestive heart failure. Am J Med. 1990;89:303-7.
40. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH, Wilson JR. Valve of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991;83:778-86.
41. Kao W, Jessup M. Exercise testing and exercise training in patients with congestive heart failure. J Heart Lung Transplant. 1994:13(suppl):S117-21.
42. Bzisehei J, Macie BM, Framer B, Topic N, Tubau J. Correlates and prognostic implication of exercise capacity in chronic congestive heart failure. Am J Cardiol. 1985; 95:1037-42.
43. Das SK, Morady F, DiCario L, Baefman J, Krol R, De Buitleir M, et al. Prognostic usefulness of programmed ventricular stimulation in dilated cardiomyopathy without symptomatic ventricular arrhythmias. Am J Cardiol. 1986;58;998-1000.
44. Poll DS, Marchlinki FE, Falcone RA, Josephson ME, Simson MB. Abnormal signal-averaged electrocardiograms in patients with nonischemic congestive cardiomyopathy: Relationship to sustained ventricular tachyarrhythmias. Circulation. 1985;72:1308-13.
45. Ohnishi Y, Inoue T, Fukaaki H. Value of the signal-averaged electrocardiogram as a predictor of sudden death in myocardial infarction and dilated cardiomyopathy. Jpn Circ J. 1990:54:127-126.
46. Bourge RC, Naftel DC, Constanzo-Nordin MR, Kirklin JK, Young JB, Kubo SH, et al. Pretransplantation risk factors for death after heart transplantation: A multi-institutional study. J Heart Lung Transplant. 1993;12:549-62.
47. Erickson KW, Costanzo-Nordin MR, O'Sullivan EJ, Johnson MR, Zucker MJ, Pifarre R, et al. Influence of pre-operative transpulmonary gradient on late mortality after orthotopic heart transplantation. J Heart Transplant. 1990;9:526-37.
48. Anguita M, Arizon JM, Valle F, Montero JA, Bueno G, Latre JM, et al. Influence on survival after heart transplantation of contraindications seen in transplant recipients. J Heart Lung Transplant. 1992;11:708-15.
49. Murali S, Kormons RL, Uretsky BF, Schechter D, Reddy PS, Denys BG, et al. Preoperative pulmonary hemodynamics and early mortality after orthotopic cardiac transplantation: The Pittsburgh experience. Am Heart J. 1993; 126:896-904.
50. Costard-Jackle A, Hill I, Schroeder JS, Fowler MB. The influence of preoperative patient characteristics on early and late survival following cardiac transplantation. Circulation. 1991;84(suppl 3):III-329-37.
51. Kirklin JK, Naftel DC, Kirklin JW, Blackstone EH, White-Williams C, Bourge RC. Pulmonary vascular resistance and the risk of heart transplantation. J Heart Transplant. 1988;7:331-6.
52. Chau EMC, Bailey KR, Mahoney DW, Frantz RP, McGregor CGA, Daly RC, et al. Predictors of reversibility of pulmonary hypertension in cardiac transplant recipients in the first postoperative year. Circulation. 1996;94(suppl II):II-267-72.
53. Kieler-Jensen N, Ricksten SE, Stenqvist O, Bergh CH, Lindelov B, Wennmalm A, et al. Inhaled nitric oxide in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. Heart Lung Transplant. 1994;13:366-75.
54. Frantz RP, Heublein DM, Burnett JC. Comparative hemodynamic and neurohumoral effects of inhaled nitric oxide and intravenous sodium nitroprusside in cardiac transplant candidates with pulmonary hypertension (abstract). J Heart Lung Transplant. 1997;16:90.
55. Kieler-Jensen N, Milocco I, Ricksten SE. Pulmonary vasodilation after heart transplantation: A comparison among prostacyclin, sodium nitroprusside, and nitroglycerin on right ventricular function and pulmonary selectivity. J Heart Lung Transplant. 1993;12:179-84.
56. Coddens J, Delooft T, Vandenbroucke G. Effects of dobutamine and/or nitroprusside on the pulmonary circulation in patients with pulmonary hypertension secondary to end-stage heart failure. J Cardiothorac Vase Anesth. 1993; 7:321-5.
57. Givertz MM, Hare JM, Loh E, Gauthier DF, Colucci WS. Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: A rapid test for reversibility of pulmonary hypertension. J Am Coll Cardiol. 1996;28:1775-80.
58. Frantz RP, Edwards BS, Olson LJ, Schwab MK, Adams TF, Textor SC, et al. Effects of pentoxifylline on renal function and blood pressure in cardiac transplant recipients: A randomized trial. Transplantation. 1997;73:1607-10.
59. Light RW, George RB. Serial pulmonary function in patients with acute heart failure. Arch Intern Med. 1993;143:429-33.
60. Young JN, Yazbeck J, Esposito G, Mankad P, Townsend E, Yacoub M. The influence of acute preoperative pulmonary infarction on the results of heart transplantation. J Heart Transplant. 1986;5:20-2.
61. Muno E, Lonquist JL, Radovancevic B, Baldwin RT, Ford S, Duncan JM, et al. Long-term results in diabetic patients undergoing heart transplantation. J Heart Lung Transplant. 1992;11:943-9.
62. Ladowski JS, Kormos RL, Uretsky BF, Griffith BP, Armitage JM, Hardesly RL. Heart Transplantation in diabetic recipients. Transplantation. 1992;49:303-5.
63. Rodriguez A, Diaz M, Colon A, Santiago-Delpin EA. Psychosocial profile of noncompliant transplant patients. Transplant Proc. 1991;23:1807-9.
64. Rovelli M, Palmeri D, Vossler E, Bartus S, Hull D, Schweizer R. Noncompliance in organ transplant recipients. Transplant Proc. 1989;21(pt 1):833-4.
65. Kuhn WF, Myers B, Brennan AF, Davis MH, Lippmann SB, Gray LA, et al. Psychopathology in heart transplant candidates. J Heart Transplant. 1988;7:223-6.
66. Freeman AM III, Folks DG, Sokol RS, Fabs JJ. Cardiac transplantation: Clinical correlates of psychiatric outcome. Psychosomatics. 1988;29:47-54.
67. Heroux AI, Costanzo-Nordin MR, O'Sullivan JE, Kao WG, Line Y, Mullen GM, et al. Heart transplantation as a treatment option for end-stage heart disease in patients older than 65 years of age. J Heart Lung Transplant. 1993;12:573-9.
68. Valantine HA. Role of lipids in allograft vascular disease: A multicenter study of intimal thickening detected by intravascular ultrasound. J Heart Lung Transplant. 1995; 14:S234-7.
69. Sambrook PN, Kelly PJ, Keogh AM, Macdonald P, Spratt P, Freund J, et al. Bone loss after heart transplantation: A prospective study. J Heart Lung Transplant. 1994;13:116-21.
70. Lee AH, Mull RL, Keenan GF, Callegari PE, Dalinka MK, Eisen HJ, et al. Osteoporosis and bone morbidity in cardiac transplant recipients. Am J Med. 1994;96(1):35-41.
71. Stevenson LW, Warner SL, Hamilton MA, Moriguchi JD, Chelimsky-Fallick C, Fonarow GC, et al. Modeling distribution of donor heart to maximize early candidate survival. Circulation. 1992;86(suppl 2):II-224-30.
72. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685-91.
73. Dickstein K, Chang P, Willenheimer R, Haunso S, Remes J, Hall C, et al. Comparison of the effects of Losartan and Enalapril on clinical status and exercise performance in patients with moderate or severe heart failure. J Am Coll Cardiol. 1995;26:438-45.
74. Cody RJ, Smith LK, Van Voorhees L, Gourley LA, Jolly MK. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors: RADIANCE Study. N Engl J Med. 1993;329: 1-7.
75. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK, on behalf of the PROVED Investigative Group. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: Results of the PROVED trial. J Am Coll Cardiol. 1993;22:955-62.
76. Digitalis Investigation Group Trial. The effect of digitalis on mortality and morbidity in patients with heart failure. New Eng J Med. 1997;336:525-33.
77. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockage in congestive cardiomyopathy. Br Heart J. 1975;37:1022-36.
78. Swedberg K, Hjalmarson A, Varnauskas E, Wallentin I. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet. 1979;1:1374-6.
79. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993;342:1441-6.
80. CIBIS Investigators. A randomized trial of beta-blockade in heart failure. The cardiac insufficiency bisoprolol study (CIBIS). Circulation. 1994;90:1765-73.
81. Eichhorn EJ, Hjalmarson A. Beta-blocker treatment for chronic heart failure: The frog prince. Circulation. 1994; 90:2153-6.
82. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomized study. J Am Coll Cardiol. 1995;25:1225-31.
83. Packer M, Bristow MR, Cohn J, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. New Engl J Med. 1996;334:1349-55.
84. Pfeffer MA, Stevenson LW. Beta-adrenergic blockers and survival in heart failure. New Engl J Med. 1996;334: 1396-7.
85. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation. 1994;89:1632-42.
86. Woodley SL, Gilbert EM, Anderson JL, O'connell JB, Deitchman D, Yanowitz FG, et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation. 1991;84:2426-41.
87. Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connell JB, Renlund DG, et al. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: A double-blind, randomized study of bucindolol versus placebo. Am J Med. 1990;88:223-9.
88. Packer M, Colucci WS, Sackner-Bernstein JD, Liang C, Goldscher DA, Freeman I, et al. Double-blind, placebo- controlled study of the effects of carvedilol in patients with moderate to severe heart failure. Circulation. 1996; 94:2793-9.
89. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN Fowler MB, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 1996;94:2800-6.
90. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996;94:2807-16.
91. Gilbert EM, Abraham WT, Olsen S, Harder B, White M, Mealy P, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996;94:2817-25.
92. Chatterjee K. Heart failure therapy in evolution. Circulation. 1996;94:2689-93.
93. Friedman AW, Minella RA, Silver SJ, Lipman RC, McEwen S. Reduced hospital admissions with chronic inotropic therapy for resistant congestive heart failure. Congestive Heart Failure. 1995;1(7):19-23.
94. Miller LW. Outpatient dobutamine for refractory congestive heart failure: Advantages, techniques, and results. J Heart Lung Transplant. 1991;10:482-7.
95. Nishimura RA, Symanski JD, Hurrell DG, Trusty JM, Haves DL, Tajik AJ. Dual-chamber pacing for cardiomyopathies: A 1996 clinical perspective. Mayo Clin Proc. 1996;71:1077-87.
96. Gold MR, Feliciano Z, Gottlieb SS, Fisher ML. Dual-chamber pacing with a short atrioventricular delay in congestive heart failure: A randomized study. J Am Coll Cardiol. 1995;26:967-73.
97. Wenger NK. Rehabilitation of the patient with heart failure and after cardiac transplantation: Recommendations of the clinical practice guideline cardiac rehabilitation. Congestive Heart Failure. 1995;1(7):11-12, 18.
98. Konstam M, Dracup K, Baker D, Bottorff MB, Brooks NH, Dacey RA, et al. Heart failure: Evaluation and care of patients with left ventricular systolic dysfunction. Clinical practice guideline no. 11. Rockville, MD: US Department of Health and Human Services, Public Health Service; June 1994. Agency for Health Care Policy and Research publication 94-0612.
99. Rose EA, Levin HR, Oz MC. Artificial circulatory support with textured interior surfaces: a counterintuitive approach to minimizing thromboembolism. Circulation. 1994;90(pt 2):II87-91.
100. Chen JM, Levin HR, Rose EA, Addonizio LJ, Landry DW, Sistino JJ, et al. Experience with right ventricular assist devices for perioperative right-sided circulatory failure. Ann Thorac Surg. 1996;61:305-10, 311-3.
101. Ashton RC Jr, Goldstein DJ, Rose EA, Weinberg AD, Levin HR, Oz MC. Duration of left ventricular assist device support affects transplant survival. J Heart Lung Transplant. 1996;15:1151-7.
102. Smith JA, Oyer PE, Stinson EB, Portnor PM, Reitz BA, Shumway NE. Bridging to cardiac transplantation with the Novacor left ventricular assist system. Asian Pacific J Thorac Cardiovasc Surg. 1994;3(1):17-24.
103. Stevenson WG, Stevenson LW, Middlekauff HR, Fonarow GC, Hamilton MA, Woo MA, et al. Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol. 1996;28(6):1458-63.
104. Natale A, Zimerman L, Tomassoni G, Kearney M, Kent V, Brandon MJ, et al. Impact on ventricular function and quality of life of transcatheter ablation of the atrioventricular junction in chronic atrial fibrillation with a normal ventricular response. Am J Cardiol. 1996;78:1431-3.
105. Daoud EG, Weiss R, Bahu M, Knight BP, Bogun F, Goval R, et al. Effect of an irregular ventricular rhythm on cardiac output. Am J Cardiol. 1996;78:1433-6.
106. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. New Engl J Med. 1996; 335:1933-40.
107. Sweeney MO, Ruskin JN, Garan H, McGovern BA, Guy ML, Torchiana DF, et al. Influence of the implantable cardioverter/defibrillator on sudden death and total mortality in patients evaluated for cardiac transplantation. Circulation. 1995;92(11):3273-81.
108. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD Deedwania PC, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med. 1995;333:77-82.
109. Doral HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R for Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet. 1994;344:493-8.
110. Morgantaler A, Bruning CO III, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA. 1996;276:1904-6.
111. Edwards BS, Hunt SA, Fowler MB, Valantine HA, Schroeder JS. Cardiac transplantation in patients with preexisting neoplasms. Am J Cardiol. 1990;65:501-6.